Title: Investing in Therapies that Accelerate Health Equity
1- Syridex Bio is an impact-driven, life
sciences-focused firm investing in therapies that
accelerate global health equity by addressing the
needs of underserved communities. Syridex Bio was
founded on the belief that everyone deserves the
opportunity to live a healthy life. For too long,
deep inequities have persisted across our
pharmaceutical, biotechnology, and medical
systems. Despite increased public attention on
the problem in recent years, progress remains far
too slow. At Syridex Bio, we are addressing this
gap in the market by strategically investing in
therapies that treat diseases disproportionately
affecting minoritized communities. By financing
the development of drugs and treatments
addressing the worlds greatest health
disparities, we are convinced that we can
accelerate health equity globally and achieve
strong financial returns for our investors.
2TeamMeet the leaders guiding our work
3ApproachApproachExplore our investment
philosophy and strategy
4About Us
- Syridex Bio was founded on the belief that
everyone deserves the opportunity to live a
healthy life. For too long, deep inequities have
persisted across our pharmaceutical,
biotechnology, and medical systems. Despite
increased public attention on the problem in
recent years, progress remains far too slow. - At Syridex Bio, we are addressing this gap in the
market by strategically investing in therapies
that treat diseases disproportionately affecting
underserved communities. By financing the
development of drugs and treatments addressing
the worlds greatest health disparities, we are
convinced that we can accelerate health equity
globally and achieve strong financial returns for
our investors.
5Founding Investment Team
Squire ServanceREAD BIO
6Advisory Board
Anindya Roychowdhury READ BIO
Owen May READ BIO
Veleka Peeples-Dyer READ BIO
Kamil Ali-Jackson READ BIO
Kelvin A. Baggett, MD READ BIO
7Investment Approach
Investment Focus We draw on our deep
relationships across the global pharmaceutical
and biotech industries to source innovative,
best-in-class clinical stage or near-clinical
stage therapies for diseases that
disproportionately affect underserved
communities. Then, we invest in development to
bring to market novel drugs and treatments that
might otherwise go undeveloped. Investment
Strategy We invest along two primary strategies
venture creation and private equity. Venture
Creation Building sustainable companies around
innovative products we acquire from life sciences
companies and institutions Private Equity
Privatizing and creating value for undervalued
public pharmaceutical and biotechnology
companies Investment Team Our team is focused on
accelerating health equity and eliminating health
disparities around the world. MEET OUR TEAM
8Contact Us info_at_syridexbio.com 300 Carnegie
Center, Suite 150, Princeton, NJ 08540